AbCellera (ABCL) Q3 2026 earnings review
AbCellera's hot-flash drug succeeds, but it halts its second trial
AbCellera, a developer of antibody drugs, cleared its biggest clinical hurdle while new partner contracts revived its research revenue. Chief executive Carl Hansen said the mid-stage trial for its lead hot-flash drug ABCL635 cut symptom frequency by 83% versus 33% on a dummy injection, allowing the company to raise $200 million in new equity. Research fees rebounded to $11 million — more than double what the Jazz contract schedule pointed to by our math — and deferred revenue climbed to $83 million.
| Research fee revenue | $10.5M +20% from a year ago; $3.9M last quarter |
|---|---|
| Total deferred revenue | $83.1M up from $61.2M last quarter |
| ABCL635 Phase 2 hot-flash reduction | -83% -33% on placebo at week 4 |
| 2027 ABCL635 clinical plan | Unchanged late-stage menopause trial plus 2 cancer VMS trials |
⚖️ Verdict: 🟢 Bullish
The story got better because the positive Phase 2 readout removed the risk that a high placebo response would sink the company's lead drug, while the equity sale and partner upfronts pushed cash and marketable securities to $791 million. One caution: the company decided not to advance its second clinical drug, ABCL575, past Phase 1 despite positive safety data, leaving the clinical pipeline reliant on ABCL635 until pre-clinical candidates enter human trials.
The question now is whether the biotechnology group can turn ABCL635 into a commercial contender while keeping its research fee recovery going. Supporters point to the 50-point advantage over placebo and $83 million of booked partner work, while skeptics note that competing daily pills are already on the market and older partner programs fell again to 34. Early 2027 data on 12-week symptom durability will provide the next test.
🐂 Bull Case
Lead Hot-Flash Drug Cleared Its Mid-Stage Trial
ABCL635 is AbCellera's antibody drug designed as a monthly injection to treat vasomotor symptoms (VMS), the medical term for menopausal hot flashes. Critics warned that a high response in the dummy-pill group could sink the small 92-patient trial, and noted that two daily pills from rivals already sell in this market. Chief executive Carl Hansen said the Phase 2 trial results have the potential to "redefine the treatment of hot flashes".
- Symptom frequency at week 4: down 83% on the drug versus 33% on placebo
- Complete resolution of moderate to severe hot flashes: 37% of treated patients versus 2% on placebo
- Serious or severe side effects in the drug group: zero across 46 patients
The 50-percentage-point advantage over placebo cleared the efficacy bar and resolved the trial's placebo risk, while showing no meaningful liver or stomach side effects. That safety record matters because competing daily pills require liver monitoring or cause nausea, though AbCellera must still prove its edge in a larger Phase 3 trial.
What to watch: the 12-week and open-label extension data due in early 2027. Sustained symptom relief without new liver signals will determine the design of the final Phase 3 trials.
New Partner Deals Turned Research Fees Around
AbCellera earns research fees when pharmaceutical partners pay it to discover antibody drugs, including T-cell engagers that guide the immune system to attack targets. Research fees had fallen for three straight quarters as older discovery work wound down, dropping to $3.9 million last quarter.
In the third quarter, research fees jumped to $10.5 million, up 20% from a year ago and more than double the $4.2 million implied by our math from the Jazz contract schedule alone. Total deferred revenue, which is upfront cash from partners waiting to be booked as work is completed, climbed by $21.9 million from last quarter to $83.1 million as the July payment from Vertex arrived.
What to watch: fourth-quarter research fees and the deferred revenue balance. Another quarter above $10 million will show whether the Jazz and Vertex contracts have established a higher quarterly revenue base.
Equity Raise and Cost Cuts Lifted Cash
Moving proprietary drugs into late-stage human trials requires hundreds of millions of dollars. Four days after reporting the positive hot-flash trial data in August, the Canadian biotechnology group sold about 20 million shares and pre-funded warrants at $9.75 apiece, bringing in $188.8 million in net cash and lifting the diluted share count by 6.4% from a year ago.
At the same time, management cut sales, general, and administrative overhead by 45% from a year ago to $13.6 million, or by 151 percentage points of revenue, following the end of patent litigation earlier this year. Combined with partner upfront payments, total cash, equivalents, restricted cash, and marketable securities rose to $791 million.
What to watch: quarterly operating cash burn as Phase 3 preparations begin in 2027. The pace of trial spending will dictate how much of the $791 million cash pile remains when the lead drug finishes late-stage testing.
🐻 Bear Case
Second Clinical Drug Stopped After Early Trial
"Together with the top-line Phase 1 readout of ABCL575 and the addition of three new pipeline programs, ABCL992, ABCL385, and ABCL646, we have delivered on all corporate priorities for 2026," Hansen said. ABCL575 is an antibody targeting OX40 ligand to treat eczema and other autoimmune conditions, and it was one of only two company-owned drugs in human testing.
While the 40-person Phase 1 study met its safety goals and showed a 65-day half-life that "supports an extended dosing interval" of every 12 weeks, "AbCellera currently does not plan to develop ABCL575 past Phase 1." Stopping internal work on the drug leaves the clinical pipeline dependent on ABCL635 until pre-clinical candidates enter human trials next year.
What to watch: whether the drug developer signs an out-licensing partner for ABCL575 over the next two quarters. Without a partner to pay for Phase 2, the company gets no financial return from the completed trial.
Older Partner Programs Continue to Shrink
Before building its own drugs, AbCellera discovered antibodies for dozens of partners in exchange for small stakes in future milestone payments and sales royalties. Starting this year, the company switched to reporting only partnered programs it believes are actively progressing.
That active partner portfolio dropped again in the third quarter to 34 programs, down from 35 in June and 44 at the end of 2025. The count of partnered and internal molecules in human trials held flat from June at 12, down from 14 at the start of the year, while quarterly licensing and royalty revenue fell 35% from a year ago to $90,000.
What to watch: the progressing partner program count in the fourth-quarter report. Continued attrition below 34 programs will further reduce the odds that an older partnered molecule ever delivers commercial royalties.
Risks this quarter didn't answer
Four standing financial and timeline questions received no update in the third-quarter press release or slide presentation.
- Joint-venture office sublease: no financial terms or impairment figures for the Beedie joint-venture space, where a $38.4 million partner loan matures in February 2027.
- Late-stage trial costs: no budget disclosed for the 2027 Phase 3 menopausal study and the two new cancer hot-flash trials.
- Government funding conditions: over $100 million of government funding sits in the $890 million liquidity total, but the full quarterly filing is needed to track milestone gates and future repayment rules.
- Pre-clinical timelines: no exact 2027 quarter given for when ABCL688 and ABCL386 will enter human trials after ABCL688's application slipped from mid-2026 into 2027.
👓 Other Themes
Three New Drug Candidates Entered Pre-Clinical Work
After missing its own target to nominate a new drug candidate in the first half of 2026, AbCellera added three programs to pre-clinical testing this quarter. They include ABCL992, a "next-generation half-life extended analog of ABCL635" built for less frequent hot-flash dosing, alongside ABCL385 for an undisclosed cancer target and ABCL646 for an undisclosed ion-channel target. All three now join ABCL688 and ABCL386 in pre-clinical preparation before human trial applications.
💲 Other KPIs
Research and development spending fell 20.9% from a year ago and 5.3% from last quarter. The third quarter of 2025 carried $15.0 million of concentrated start-up costs for the two clinical trials, so completing early dosing lowered the quarterly expense bill and helped narrow the total net loss by 28.6% to $40.8 million.
Uncollected customer bills and accrued payments dropped 69.2% from $58.3 million at the end of 2025. Collecting last year's patent settlement and new partner research fees brought in $21.1 million of working-capital cash over the first nine months, lifting nine-month operating cash flow to positive $19.3 million.
Capital spending on buildings and equipment fell to $1.6 million in the third quarter by our math, down from $8.9 million a year ago and $2.1 million in the second quarter. The drug developer finished paying for its clinical manufacturing plant in late 2025, reducing nine-month capital outflows by 77.0% to $7.6 million.
🔮 Guidance
Unchanged. Management now plans to report 12-week and open-label extension data from the Phase 2 trial in early 2027 and start late-stage development for menopausal hot flashes in 2027. The biotechnology company is currently in discussions with regulators through the Food and Drug Administration's model-informed drug development program to finalize the trial design.
Unchanged. The group will start two new clinical trials in 2027 testing ABCL635 for hot flashes caused by hormone-blocking therapies in breast cancer and prostate cancer patients. Expanding into cancer treatment side effects adds two patient groups beyond menopause for the same monthly antibody injection.
❓ Key Questions
Will AbCellera license out ABCL575 or shelve it?
The company stopped internal development of its OX40 ligand antibody after Phase 1 despite a 65-day half-life. Investors need to know whether management is actively negotiating with partners to take over Phase 2 or writing the program off.
What will the three 2027 ABCL635 clinical trials cost?
Starting a late-stage menopausal study alongside two cancer hot-flash trials in 2027 will raise external clinical expenses. Management has not stated whether it will fund Phase 3 alone from its $791 million cash balance or seek a commercial co-development partner.
How much of Q3 research fees came from Jazz and Vertex?
Research fees jumped from $3.9 million to $10.5 million in the third quarter while deferred revenue rose to $83.1 million. The full quarterly filing's revenue note will show how fast the $28 million Vertex payment and $56 million Jazz payment are converting into quarterly revenue.
What is the status of the Beedie joint-venture sublease?
Last quarter's filing disclosed plans to sublease the office and lab space built through the Beedie joint venture, where a $38.4 million partner loan matures in February 2027. The press release gave no update on sublease terms or potential lease write-downs.